What is the significance of CARsgen’s Claudin18.2 CAR-T approval in China?

China’s approval of CARsgen Therapeutics’ Claudin18.2-targeted CAR-T marks the world’s first solid tumor clearance for this therapy type. It breaks the precedent of CAR-T success limited to blood cancers and validates Claudin18.2 as a viable target, signaling a major milestone for solid tumor immunotherapy and future global cell therapy innovation.